|
| 产品描述 |
| ZLD1039 is a potent, highly selective, and orally bioavailable small molecule inhibitor of EZH2, which inhibited breast tumor growth and metastasis. ZLD1039 considerably inhibited EZH2 methyltransferase activity with nanomolar potency, decreased global histone-3 lysine-27 (H3K27) methylation, and reactivated silenced tumor suppressors connected to increased survival of patients with breast cancer. Comparable to conditional silencing of EZH2, its inhibition by ZLD1039 decreased cell proliferation, cell cycle arrest, and induced apoptosis. ZLD1039 is a promising treatment for breast cancer. |
| 化学结构 |
 |
| 化学名称 |
| 3-[Ethyl(tetrahydro-2H-pyran-4-yl)amino]-N-[(2,3,5,6,7,8-hexahydro-1-methyl-3-oxo-4-isoquinolinyl)methyl]-2-methyl-5-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-benzamide |
| SMILES Code |
| O=C(NCC1=C2CCCCC2=C(C)NC1=O)C3=CC(C4=CC=C(N5CCN(C)CC5)N=C4)=CC(N(CC)C6CCOCC6)=C3C |
| 基本信息 |
产品编号:XM358
产品名称:ZLD1039
别名:ZLD1039; ZLD-1039; ZLD 1039.
CAS#:1826865-46-6
分子式:C36H48N6O3
精确分子量:612.3788
分子量:612.819
|
| 物化性质 |
外观: 白色或类白色固体粉末
纯度: >98%
运输信息: 非危险化学品，适于常温或冰袋运输。
储存条件: 低温，干燥，避光。
溶解性: 溶于DMSO, 不溶于水
储存期限:3年 -20℃固体储存
2 年 -80℃ 溶液储存 |
该产品只供科研使用，不能给病人提供。
|
|
|
